AGTR1 blockers and ACE-1 inhibitors (reviewed by Kehoe et al. (13)), or experimental activation of the counter-regulatory RAS pathway (14), are protective against the onset of cognitive decline and disease pathology in rodent models of AD. Here, ACE is linked to Alzheimer disease.